

20 **ORCID & Email:**

21 Hiroe Konishi ID: <https://orcid.org/0000-0003-4267-1665> Email hiroe-k@hyo-med.ac.jp

22 Mai Morimoto ID: <https://orcid.org/0009-0005-3703-5922> Email mai-m@hyo-med.ac.jp

23 Masayoshi Nakano ID: <https://orcid.org/0000-0003-0667-8093> Email [24 \[med.ac.jp\]\(mailto:ms-nakano@hyo-med.ac.jp\)](mailto:ms-nakano@hyo-</p></div><div data-bbox=)

25 Masahiro Koshihara ID: <https://orcid.org/0000-0002-0839-1005> Email [26 \[med.ac.jp\]\(mailto:mkoshihara@hyo-med.ac.jp\)](mailto:mkoshihara@hyo-</p></div><div data-bbox=)

27 Kosaku Murakami ID: <https://orcid.org/0000-0001-5981-4648> Email [28 \[u.ac.jp\]\(mailto:kosaku@kuhp.kyoto-u.ac.jp\)](mailto:kosaku@kuhp.kyoto-</p></div><div data-bbox=)

29 Hideo Onizawa ID: <https://orcid.org/0009-0002-9372-726X> Email [30 \[u.ac.jp\]\(mailto:honizawa@kuhp.kyoto-u.ac.jp\)](mailto:honizawa@kuhp.kyoto-</p></div><div data-bbox=)

31 Akira Onishi ID: <https://orcid.org/0000-0002-3120-1273> Email aonishi@kuhp.kyoto-u.ac.jp

32 Takayuki Fujii ID: <https://orcid.org/0000-0002-6556-1226> Email fujiiit@kuhp.kyoto-u.ac.jp

33 Koichi Murata ID: <https://orcid.org/0000-0002-7896-3937> Email kchm@kuhp.kyoto-u.ac.jp

34 Masao Tanaka ID: <https://orcid.org/0000-0002-8942-2933> Email [35 \[u.ac.jp\]\(mailto:masatana@kuhp.kyoto-u.ac.jp\)](mailto:masatana@kuhp.kyoto-</p></div><div data-bbox=)

36 Akio Morinobu ID: <https://orcid.org/0000-0002-4672-638X> Email [37 \[u.ac.jp\]\(mailto:morinobu@kuhp.kyoto-u.ac.jp\)](mailto:morinobu@kuhp.kyoto-</p></div><div data-bbox=)

38

39 ***Corresponding author**

40 Masahiro Koshiba

41 Email mkoshiba@hyo-med.ac.jp.

42 **Running title:** Serum MMP-3 Leads To Future Joint Destruction

43

44 **Statements and Declarations:**

45 **Competing Interests**

46 The Department of Advanced Medicine for Rheumatic Diseases in Kyoto University is
47 supported by Nagahama City, Shiga, Japan, Toyooka City, Hyogo, Japan, and five
48 pharmaceutical companies (Mitsubishi Tanabe Pharma Co., Chugai Pharmaceutical Co. Ltd,
49 UCB Japan Co. Ltd, AYUMI Pharmaceutical Co., and Asahi Kasei Pharma Corp.). It is also
50 supported by a grant from Daiichi Sankyo Co. Ltd. The above-mentioned pharmaceutical
51 companies were not involved in the study design, data collection and analysis, manuscript
52 writing, or manuscript submission.

53 KMurakami received speaker fees and/or consulting fees from Eisai Co. Ltd., Chugai
54 Pharmaceutical Co. Ltd., Pfizer Inc., Bristol-Myers Squibb, Mitsubishi Tanabe Pharma
55 Corporation, UCB Japan Co. Ltd., Daiichi Sankyo Co. Ltd., and Astellas Pharma Inc.

56 HO received research grants and/or speaker fees from AbbVie, Asahi Kasei, Astellas Pharma
57 Inc., Eisai Co. Ltd., Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma Corporation, and
58 Daiichi Sankyo Co. Ltd.

59 AO received research grants and/or speaker fees from Pfizer Inc., Bristol-Myers Squibb.,
60 Advantest, Asahi Kasei Pharma Corp., Chugai Pharmaceutical Co. Ltd., Eli Lilly Japan K. K.,
61 Ono Pharmaceutical Co., UCB Japan Co., Mitsubishi Tanabe Pharma Co., Eisai Co. Ltd.,
62 AbbVie Inc., Takeda Pharmaceutical Co. Ltd., and Daiichi Sankyo Co. Ltd.

63 TF received speaker fees from AbbVie, Asahi Kasei, Jansen, Tanabe Mitsubishi, and Eisai.

64 KMurata received speaker and/or consulting fees from AbbVie G.K., Eisai Co., Ltd., Pfizer Inc.,
65 Chugai Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Pfizer Inc., Bristol-
66 Myers Squibb, Daiichi Sankyo Co. Ltd., and Asahi Kasei Pharma Corp.

67 MT received research grants and speaker fees from AbbVie G.K., Asahi Kasei Pharma
68 Corporation, Astellas Pharma Inc., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd.,
69 Eisai Co., Ltd., Eli Lilly and Company, Pfizer Inc., UCB Japan Co., Ltd., Janssen Pharmaceutical
70 K.K., Kyowa Kirin Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Taisho Pharma Co., Ltd.,
71 and Teijin Pharma, Ltd.

72 AM received honorarium from AbbVie G.K., Chugai Pharmaceutical Co. Ltd., Eli Lilly Japan
73 K.K., Eisai Co. Ltd., Pfizer Inc., Bristol-Myers Squibb., Mitsubishi Tanabe Pharma Co., Astellas
74 Pharma Inc., and Gilead Sciences Japan.

75 AM received research grants from AbbVie G.K., Asahi Kasei Pharma Corp., Chugai
76 Pharmaceutical Co. Ltd., Mitsubishi Tanabe Pharma Co., and Eisai Co. Ltd. for work outside
77 the scope of this study.

78 HK, MM, MN, and MK declare no conflicts of interest.

79 **Funding**

80 Open access funding provided by the Hyogo Medical University.

81 **Acknowledgements**

82 The authors thank the patients and medical staff of both hospitals for their contribution to
83 this study. We would like to extend our heartfelt gratitude to Haruo Horii, Naohiro Ito, and
84 Masatoshi Fujii for their generous financial support for the KURAMA cohort. The funders
85 were not involved in the study design, data collection, analysis, interpretation of the data,
86 writing of the manuscript, or in any decision to publish the results. We also thank Enago
87 (www.enago.jp) for the English language review.

88 **Author contributions**

89 HK, MM, and MK contributed to design, data acquisition and analysis, statistical calculations,
90 and manuscript writing. KMurakami, HO, AO, TF, KMurata, MT, AM, and MN contributed to
91 the data analysis. All co-authors contributed substantially to the concept and revisions. They
92 approved the final version for submission.

93

94 **Abstract**

95 **Introduction.** This study aimed to evaluate whether a long-term increase in serum matrix
96 metalloproteinase-3 (MMP-3) levels leads to joint destruction in rheumatoid arthritis (RA)
97 patients with negative serum C-reactive protein (CRP) values after methotrexate (MTX)
98 therapy.

99 **Methods.** Patients with RA (n = 182) whose CRP values became negative due to MTX therapy
100 were divided into two groups based on their MMP-3 positivity at the end of the observation
101 period, and the 1-year progression of joint destruction was retrospectively compared.
102 Radiological joint destruction was assessed using the modified van der Heijde total sharp
103 score (mTSS).

104 **Results.** Among 109 (MMP-3(-), n = 63; MMP-3(+), n = 46) patients who achieved low
105 disease activity or clinical remission (28 joint disease activity score erythrocyte
106 sedimentation rate < 2.6), joint destruction (Δ mTSS \geq 0.5) progressed in 24.6% and 48.9% of
107 the MMP-3(-) and MMP-3(+) groups (p < 0.01), respectively. Prednisolone-induced increases
108 in serum MMP-3 levels also resulted in joint destruction.

109 **Conclusion.** To prevent progressive joint destruction, the target MMP-3 value is 49.7 ng/mL
110 in female patients, which is below the current MMP-3 cutoff value of 59.7 ng/mL. Residual
111 MMP-3 activity may lead to the progression of joint destruction in patients with RA, even
112 after CRP normalization by successful treatment with MTX.

113

114 **Keywords:** Rheumatoid arthritis, matrix metalloproteinase-3, C-reactive protein, modified
115 van der Heijde total sharp score, joint destruction

116

117 **INTRODUCTION**

118 Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by
119 chronic synovitis and joint destruction, which leads to disability [1]. According to current
120 recommendations, achieving clinical remission is the therapeutic target for patients with RA,
121 with low disease activity (LDA) considered the best possible alternative. A treat-to-target
122 strategy should be employed when treating patients with RA, and treatment decisions
123 should be based on disease activity and other patient factors, such as comorbidities and the
124 progression of structural damage [2, 3].

125 Methotrexate (MTX) is recommended as the first-line drug for the initial treatment
126 of RA [4, 5]. MTX remains the anchor drug in RA. MTX is not only an efficacious conventional
127 synthetic (cs) disease-modifying antirheumatic drug (DMARD) but is also the basis for
128 combination therapies, either with prednisolone (PSL) or with other csDMARDs, biological
129 DMARDs (bDMARDs), or targeted synthetic DMARDs (tsDMARDs) [6]. While serum CRP
130 values often become negative after MTX therapy, joint destruction can still progress in some
131 cases [7].

132 Matrix metalloproteinases (MMPs) are a family of enzymes that catalyze
133 extracellular matrix degradation. Most MMPs are secreted as inactive preproteins that are

134 activated when cleaved by extracellular proteinases [8]. MMP-3 is a proteinase secreted by
135 synovial fibroblasts and chondrocytes in joints. In RA, joint destruction can be accelerated by
136 active MMP-3, and serum MMP-3 levels in RA have been well evaluated as an indicator of
137 disease activity. In RA, the level of MMP-3 within the joints is markedly higher than that of
138 other MMPs [9]. This high MMP-3 level is believed to mediate joint destruction in patients
139 with RA [10, 11].

140 Increases in serum MMP-3 levels are observed from early to advanced stages in
141 80%–90% of patients with RA. Serum MMP-3 levels in patients with RA reflect the degree of
142 synovial proliferation and may serve as a prognostic indicator of disease progression,
143 particularly in early RA onset [12]. Elevated or increasing serum MMP-3 levels in patients
144 with RA are associated with the rapid progression of joint destruction. Conversely, serum
145 MMP-3 levels decrease when the condition stabilizes in response to the therapeutic effect of
146 DMARDs, including bDMARDs [13]. There are sex differences in serum MMP-3 levels; the
147 upper limits of the reference range are 121.0 and 59.7 ng/mL for male and female
148 individuals, respectively. Researchers have reported that normal serum MMP-3 levels, in
149 combination with CRP levels or disease activity, are useful for predicting clinical remission
150 and normal physical function in patients with RA [14]. However, progression of joint
151 destruction is observed even in patients with RA with negative CRP values, disease activity in
152 remission, or LDA [15]. Therefore, we observed patients with RA with negative CRP values
153 during MTX monotherapy or combination therapy for 1 year and investigated whether
154 serum MMP-3 levels are correlated with joint destruction. Furthermore, in this study, we
155 developed an ideal cutoff value for MMP-3 based on the relationship between blood MMP-3

156 levels and joint destruction.

157

158 **METHODS**

159 **Study design and patient selection**

160 The retrospective study enrolled patients who visited Hyogo Medical University
161 Hospital or Kyoto University Hospital between April 1, 2011 to April 30, 2021 and met the
162 1987 and/or 2010 RA classification criteria. Patients with RA (n = 182) whose CRP values
163 became negative following MTX monotherapy or DMARD combination therapy (MTX
164 together with other DMARDs) were divided into two groups based on their serum MMP-3
165 positivity at the end of the observation period, and the 1-year progression of joint
166 destruction was retrospectively compared through X-rays.

167

168 **Assessment**

169 The medical records of the patients, including information related to the visual
170 analog scale (VAS), CRP, erythrocyte sedimentation rate (ESR), rheumatoid factor (RF), serum
171 MMP-3, anti-citrullinated protein antibody (ACPA), 28 joint disease activity score (DAS28),
172 and clinical disease activity index (CDAI), were retrospectively reviewed by two authors (HK,
173 MM). Patients who had moderate or severe renal dysfunction (eGFR_{cre} < 45 mL/min/1.73
174 m²) or were taking oral PSL > 25 mg/day were excluded. After the observation period, the

175 patients were divided into the serum MMP-3 positive (MMP-3(+)) and MMP-3 negative
176 (MMP-3(-)) groups based on whether their serum MMP-3 levels were above or below the
177 upper reference limit for each sex. Progression was assessed via radiography of the hands,
178 wrists, and feet and scored chronologically using the mTSS method recommended by
179 Bruynesteyn et al. [16]. Radiographs of each patient's hands and feet were taken upon the
180 initiation of MTX therapy and 1 year after MTX therapy. Radiographic progression was
181 evaluated independently by two rheumatologists (MM and KMurakami), who were trained
182 and certified by Prof. van der Heijde (Leiden University) for the mTSS scoring system.
183 Moreover, mTSS progression after 1 year (Δ mTSS) was calculated from the mean progression
184 determined by the two readers. If Δ mTSS differed by ≥ 10 , the two rheumatologists discussed
185 and reached a consensus. Patients were classified as having structural remission (Δ mTSS <
186 0.5) or radiographic evidence of progression (Δ mTSS ≥ 0.5).

187

188 **Ethical approval**

189 The retrospective study protocol was approved by the Ethics Committee of Hyogo
190 Medical University (Protocol No. 3923). This retrospective study waived the requirement for
191 individual informed consent owing to the "opt-out" principle. Patients were allowed to "opt-
192 out" of the database if they wished. Clinical data at Kyoto University were approved by the
193 Medical Ethics Committee of the Kyoto University Graduate School and Faculty of Medicine
194 (No. R0357), and written informed consent to participate in the study was obtained from all
195 patients of Kyoto University Hospital.

196 **Statistical analysis**

197 All statistical analyses were performed using IBM SPSS Statistics version 29 (IBM
198 Corp., Armonk, NY, USA). Fisher's exact test was used for categorical variables. Receiver
199 operating characteristic (ROC) curve analysis was used to determine the cutoff value and p-
200 values of <0.05 were considered statistically significant.

201

202 **RESULTS**

203 **Clinical characteristics of patients upon the initiation of MTX**

204 **therapy**

205 Of the patients who continued MTX monotherapy or DMARD combination therapy
206 for at least 1 year, 182 (including 142 females) could be evaluated radiographically. Upon
207 initiation of MTX therapy, participants had a mean age of 59.1 ± 12.1 years, with a mean
208 disease duration of 9.3 ± 10.1 years. Among them, 64.2% were RF-positive, 64.2% were
209 ACPA-positive, and 56.0% were both RF- and ACPA-positive. The mean DAS28-ESR was $2.46 \pm$
210 0.98 , the mean CDAI was 4.51 ± 5.48 , the mean MTX dose was 7.0 ± 2.7 mg/week in 125
211 (68.7%) patients, and the mean PSL dose was 4.1 ± 2.6 mg/day in 76 patients (41.8%) (Table
212 1).

213 **Table 1. Subject demographics and clinical characteristics at 0week**

Parameter	
-----------	--

Age (years)	59.1 ± 12.1
Female, n (%)	142 (78.0%)
RA duration (years)	9.3 ± 10.1
RF positive	64.2%
ACPA positive	64.2%
RF & ACPA positive	56.0%
DAS28 (ESR)	2.46 ± 0.98
CDAI	4.51 ± 5.48
MTX use at baseline, n (%)	125 (68.7)
MTX dose (mg/w)	7.0 ± 2.7
PSL use at baseline, n (%)	76 (41.8)
PSL dose (mg)	4.1 ± 2.6

214 Values are presented as mean ± standard deviation unless stated otherwise.

215 CCP, cyclic citrullinated peptide; MTX, methotrexate; RA, rheumatoid arthritis; RF,
216 rheumatoid factor; DAS28, Disease Activity Score 28-joint assessment; CDAI, Clinical Disease
217 Activity Index; PSL, prednisolone.

218

219 **Comparison of the progression of joint damage estimated by**

220 **radiography in the MMP-3(-) and MMP-3(+) groups**

221 The progression rates of joint destruction in the MMP-3(-) (n = 100) and MMP-3(+)
222 groups (n = 82) were 22.5% (n = 23) and 42.1% (n = 35), respectively (p < 0.01). Changes in
223 the mTSS from baseline (Δ mTSS) were 0.46 ± 1.12 and 0.97 ± 1.99 (p = 0.03) (Fig. 1A), and
224 the nonprogression rates (Δ mTSS < 0.5) were 77.5% and 57.9%, respectively (Fig. 1B). At
225 baseline, the PSL usage rates were 26.0% (n = 26) and 61.0% (n = 50). The progression of
226 joint destruction was examined in 106 of these 182 patients (MMP-3(-), n = 74; MMP-3(+), n

227 = 32) who were PSL-free. Among these patients, the progression rates of joint destruction
228 were 23.6% (n = 18) and 48.4% (n = 16) in the MMP-3(-) and MMP-3(+) groups, respectively
229 (p = 0.01). The Δ mTSS values were 0.53 ± 1.24 and 1.16 ± 1.98 (p = 0.05) (Fig. 1C), and the
230 nonprogression rates were 76.4% and 51.6%, respectively (Fig. 1D).

231 Even when the CRP value becomes negative at 52 weeks, it does not necessarily
232 indicate the absence of inflammation. We sometimes encounter patients with a few small
233 joint swellings and negative CRP values. Thus, we examined the progression of joint
234 destruction in 97 of these 182 patients with no swollen joints at 52 weeks (MMP-3(-), n =
235 58; MMP-3(+), n = 39). Among these patients, the progression rates of joint destruction
236 were 19.8% (n = 12) and 42.3% (n = 17) in the MMP-3(-) and MMP-3(+) groups, respectively
237 (p = 0.02). The Δ mTSS values were 0.37 ± 0.89 and 1.18 ± 2.45 (p = 0.02) (Fig. 1E), and the
238 nonprogression rates were 80.2% and 57.7%, respectively (Fig. 1F). The PSL usage rates at
239 baseline were 27.6% (n = 16) and 53.8% (n = 21), respectively. We found no correlation
240 between CRP and MMP-3 in 182 patients (Fig. 1G); therefore, joint destruction progresses
241 more likely in the MMP-3(+) group than in the MMP-3(-) group (Table 2).

242

243 **Fig 1. Progression of joint destruction was analyzed in the MMP-3(-) and MMP-3(+) groups**
244 **at 52weeks.** (A) Patients with rheumatoid arthritis (n = 183), change from baseline in the
245 modified total sharp score (Δ mTSS). (B) Patients with rheumatoid arthritis (n = 183),
246 cumulative probability plot of mTSS. (C) Patients with PSL-free rheumatoid arthritis (n = 106),
247 change from baseline in Δ mTSS. (D) Patients with PSL-free rheumatoid arthritis (n = 106),

248 cumulative probability plot of mTSS. (E) Patients with no swollen joints at 52 weeks (n = 97),
 249 change from baseline in the modified total sharp score (Δ mTSS). (F) Patients with no swollen
 250 joints at 52 weeks (n = 97), cumulative probability plot of mTSS. (G) Correlations between
 251 CRP and MMP-3 values in 182 patients. Values in (A)(C)(E) indicate the mean (SD) at each
 252 time point and in the MMP-3(-) or MMP-3(+) group. Percentages in (B)(D)(F) indicate the
 253 progression rates of joint destruction (Δ mTSS > 0.5) in the MMP-3(-) or MMP-3(+) group.

254 **Table 2. MMP-3 (-) group or MMP-3 (+) group analysis at 52weeks**

Parameter	MMP-3 (-)	MMP-3 (+)	p value
Age (years)	58.1 ± 11.4	62.5 ± 12.6	0.01
Female / Male	73 / 27	69 / 13	0.07
RA duration (years)	9.3 ± 10.3	11.6 ± 9.8	0.17
RF positive	52.6%	76.9%	< 0.01
ACPA positive	54.4%	75.0%	0.02
RF & ACPA positive	43.9%	69.2%	< 0.01
DAS28 (ESR)	2.29 ± 1.02	2.67 ± 0.9	0.03
CDAI	4.11 ± 6.20	4.98 ± 4.48	0.37
mTSS baseline (week 0)	27.6 ± 45.7	39.8 ± 52.8	0.1
Δ mTSS	0.46 ± 1.12	0.97 ± 1.99	0.03
0.5 \leq Δ baseline, n (%)	23 (23.0)	35 (42.7)	
progression ratio	22.5	42.1	< 0.01
Without PSL use at baseline, n	74	32	
Δ mTSS	0.53 ± 1.24	1.16 ± 1.98	0.05
0.5 \leq Δ baseline, n (%)	18 (24.3)	16 (50.0)	
progression ratio	23.6	48.4	0.01
no swollen joints group, n	58	39	
Δ mTSS	0.37 ± 0.89	1.18 ± 2.45	0.02

0.5 \leq Δ baseline, n (%)	12 (20.7)	17 (43.6)	
PSL use at baseline, n (%)	16 (27.6)	21 (53.8)	
progression ratio	19.8	42.3	0.02
CRP-negative group (week 0), n	79	63	
Δ mTSS	0.50 \pm 1.20	1.16 \pm 2.20	0.02
0.5 \leq Δ baseline, n (%)	19 (24.1)	29 (46.0)	
PSL use at baseline, n (%)	19 (24.1)	36 (57.1)	
progression ratio	25.7	46.0	< 0.01
DAS-28 : LDA and the clinical remission group, n	63	46	
Δ mTSS	0.42 \pm 1.02	1.21 \pm 2.41	0.02
0.5 \leq Δ baseline, n (%)	16 (25.4)	23 (50.0)	
PSL use at baseline, n (%)	15 (23.8)	24 (52.2)	
progression ratio	25.4	50.0	< 0.01
DAS-28 : LDA and the clinical remission group, n (without PSL use at baseline)	48	22	
Δ mTSS	0.49 \pm 1.15	1.39 \pm 2.23	0.03
0.5 \leq Δ baseline, n (%)	13 (27.1)	12 (54.5)	
progression ratio	27.1	54.5	0.03
CDAI : LDA and the clinical remission group, n	70	58	
Δ mTSS	0.36 \pm 0.83	1.19 \pm 2.23	< 0.01
0.5 \leq Δ baseline, n (%)	17 (24.3)	28 (48.3)	
PSL use at baseline, n (%)	18 (25.7)	29 (50.0)	
progression ratio	23.6	47.4	< 0.01
CDAI : LDA and the clinical remission group, n (without PSL use at baseline)	52	29	
Δ mTSS	0.42 \pm 0.93	1.19 \pm 2.03	0.02
0.5 \leq Δ baseline, n (%)	14 (26.9)	14 (48.3)	
progression ratio	26	46.6	0.08

255 Values are presented as mean \pm standard deviation unless stated otherwise.

256 DAS28, Disease Activity Score 28-joint assessment; ESR, erythrocyte sedimentation rate;
257 mTSS, modified Total Sharp Score; LDA, low Disease Activity; CDAI, Clinical Disease Activity
258 Index; PSL, prednisolone.

259

260 **Effect of PSL-induced elevation of serum MMP-3 on the progression** 261 **of joint destruction**

262 In the MMP-3(+) group, progression of joint destruction was assessed in groups
263 with (n = 46) or without (n = 36) PSL. We evaluated whether the oral PSL-induced serum
264 MMP-3 increase was relevant to the joint destruction progression. However, progression of
265 joint destruction was observed in 43.1% (n = 16) and 40.2% (n = 19) of the patients in the
266 PSL (-) and PSL (+) groups (p = 0.82); Δ mTSS values were 1.03 ± 1.90 and 0.92 ± 2.08 (p =
267 0.82) (Fig. 2A); and the nonprogression rates were 56.9% and 59.7%, respectively (Fig. 2B).
268 We found no significant difference in disease activity between the two groups (Table 3).
269 These data suggest that the increase in serum MMP-3 levels induced by PSL is also involved
270 in the progression of joint destruction.

271

272 **Fig 2. For the MMP-3+ group (n = 83), progression of joint destruction was analyzed in the**
273 **PSL(-) and PSL(+) groups at 52 weeks.** (A) Change from baseline in the modified total sharp
274 score (Δ mTSS). Values in indicate mean (SD) at each time point and in the PSL(-) or PSL(+)
275 group. (B) Cumulative probability plot of mTSS. Percentages indicate the progression rates of
276 joint destruction (Δ mTSS > 0.5) of each treatment group.

277 **Table 3. In the MMP-3 (+) group, PSL (-) group or PSL (+) group analysis at 52weeks**

Parameter	PSL (-)	PSL (+)	<i>p</i> value
MMP-3 (+) group, n	36	46	
DAS28 (ESR)	2.49 ± 0.86	2.88 ± 1.02	0.11
CDAI	3.64 ± 3.23	5.73 ± 5.05	0.06
ΔmTSS	1.03 ± 1.90	0.92 ± 2.08	0.82
0.5 ≤ Δ baseline, n (%)	16 (44.4)	19 (43.6)	
progression ratio	43.1	40.2	0.82

278 Values are presented as mean ± standard deviation unless stated otherwise.

279 DAS28, Disease Activity Score 28-joint assessment; ESR, erythrocyte sedimentation rate;
280 mTSS, modified Total Sharp Score; CDAI, Clinical Disease Activity Index; PSL, prednisolone.

281

282 **Comparison of the progression of joint damage estimated by**
283 **radiography between the MMP-3(-) and MMP-3(+) subgroups**
284 **within the CRP-negative group at baseline**

285 We examined the progression of joint destruction in 142 of 183 patients with RA
286 (MMP-3(-), n = 79; MMP-3(+), n = 63) who were CRP negative at baseline. Progression of
287 joint destruction was found in 25.7% and 46.0% ($p < 0.01$); the ΔmTSS values were 0.50 ±
288 1.20 and 1.16 ± 2.20 ($p = 0.02$) (Fig. 3A); and the nonprogression rates ($\Delta mTSS < 0.5$) were
289 74.3% and 54.0% (Fig. 3B). The PSL usage rates at baseline were 24.1% (n = 19) and 57.1% (n
290 = 36). This suggests that progression of joint destruction is likely if serum MMP-3 levels
291 remain positive, even when baseline CRP is negative (Table 2).

292

293 **Fig 3. For the CRP-negative group at baseline (n = 142), progression of joint destruction**
294 **was analyzed in the MMP-3(-) and MMP-3(+) groups at 52 weeks.** (A) Change from
295 baseline in the modified total sharp score (Δ mTSS). Values indicate mean (SD) at each time
296 point and MMP-3(-) or MMP-3(+) group. (B) Cumulative probability plot of mTSS.
297 Percentages indicate the progression rates of joint destruction (Δ mTSS > 0.5) of each
298 treatment group.

299

300 **Comparison of the progression of joint damage estimated by**
301 **radiography in the MMP-3(-) and MMP-3(+) groups with LDA or**
302 **clinical remission (DAS28-ESR < 2.6 or CDAI \leq 2.8).**

303 Clinical remission is the therapeutic target for patients with RA, with LDA being the
304 best possible alternative. Thus, the study enrolled 109 of 183 patients with RA (MMP-3(-), n
305 = 63; MMP-3(+), n = 46) who had achieved LDA or clinical remission (DAS28-ESR < 2.6). The
306 progression of joint destruction was found in 24.6% (MMP-3(-)) and 48.9% (MMP-3(+)) (p <
307 0.01); the Δ mTSS values were 0.42 ± 1.02 and 1.21 ± 2.41 (p = 0.02) (Fig. 4A); and the
308 nonprogression rates (Δ mTSS < 0.5) were 75.4% and 51.1%, respectively (Fig. 4B). The
309 progression of joint destruction was further examined in 70 of these 109 patients (MMP-3(-),
310 n = 48; MMP-3(+), n = 22) who were PSL-free. Among these patients, progression of joint
311 destruction was observed in 26.0% and 47.7% (p = 0.03), the Δ mTSS values were 0.49 ± 1.15
312 and 1.39 ± 2.23 (p = 0.03), and the nonprogression rates were 72.9% and 45.5%, respectively.

313 Similarly, 128 of 182 patients with RA (MMP-3(-), n = 70; MMP-3(+), n = 58) who had
314 achieved LDA or clinical remission (CDAI \leq 2.8) were compared. The progression of joint
315 destruction was found in 23.6% (MMP-3(-)) and 47.4% (MMP-3(+)) ($p < 0.01$), the Δ mTSS
316 values were 0.36 ± 0.83 and 1.19 ± 2.23 ($p < 0.01$) (Fig. 4C), and the nonprogression rates
317 (Δ mTSS < 0.5) were 76.4% and 52.6%, respectively (Fig. 4D). We further examined the
318 progression of joint destruction in 81 of these 128 patients (MMP-3(-), n = 52; MMP-3(+), n
319 = 29) who were PSL-free. Among these patients, we observed progression of joint
320 destruction in 26.0% and 46.6% ($p = 0.08$); the Δ mTSS values were 0.42 ± 0.93 and $1.19 \pm$
321 2.03 ($p = 0.02$); and the nonprogression rates were 74.0% and 53.4%, respectively. Joint
322 destruction was more severe in the MMP-3(+) group than in the MMP-3(-) group (Table 2),
323 indicating that neither the achievement of LDA nor clinical remission is sufficient to prevent
324 the progression of joint destruction, particularly when the serum MMP-3 levels remain
325 positive.

326

327 **Fig 4. For patients with rheumatoid arthritis in remission or with low disease activity,**
328 **progression of joint destruction was analyzed in the MMP-3(-) and MMP-3(+) groups at 52**
329 **weeks.** (A) Patients with rheumatoid arthritis in remission or with low disease activity on the
330 DAS28 (n = 109), change from baseline in the modified total sharp score (Δ mTSS). (B)
331 Patients with rheumatoid arthritis in remission or with low disease activity on the DAS28 (n
332 = 109), cumulative probability plot of mTSS. (C) Patients with rheumatoid arthritis in
333 remission or with low disease activity on the CDAI (n = 128), change from baseline in Δ mTSS.
334 (D) Patients with rheumatoid arthritis in remission or with low disease activity on the CDAI

335 (n = 128), cumulative probability plot of mTSS. Values in (A)(C) indicate mean (SD) at each
336 time point and in the MMP-3(-) or MMP-3(+) groups. Percentages in (B)(D) indicate the
337 progression rates of joint destruction (Δ mTSS > 0.5) in the MMP-3(-) or MMP-3(+) group.

338

339 **ROC analysis to determine the cutoff value of serum MMP-3 levels**

340 Finally, the optimal serum MMP-3 cutoff value was examined from the ROC curve
341 using the Youden index. PSL-free female patients were selected because serum MMP-3
342 levels are affected by sex (the upper limits of the currently used reference range for male
343 and female are 121.0 and 59.7 ng/mL, respectively) and PSL; the study included a few male
344 patients. The ROC analysis revealed that the cutoff value of serum MMP-3 level was 49.7
345 ng/mL (area under the curve, 0.681; 95% CI 0.560–0.802, and $p < 0.01$) (Fig. 5A) to achieve
346 structural remission (Δ mTSS < 0.5). In patients with advanced joint destruction (Δ mTSS \geq 0.5),
347 few patients had serum MMP-3 levels <49.7 ng/mL (Fig. 5B). Therefore, in female patients
348 with RA, lowering the serum MMP-3 level to <49.7 ng/mL is desirable to prevent the
349 progression of joint destruction.

350

351 **Fig 5. ROC analysis to determine the cutoff value of serum MMP-3 levels.** (A) The ROC
352 analysis revealed the cutoff value of the serum MMP-3 was 49.7 ng/ml (area under the
353 curve: 0.681, 95%CI: 0.560–0.802, $p < 0.01$) to achieve Δ mTSS < 0.5. (B) In the group of
354 patients with advanced joint destruction (Δ mTSS \geq 0.5), patients had serum MMP-3 levels

355 more than 49.7 ng/ml.

356

357 **DISCUSSION**

358 Progressive joint destruction is often observed during RA treatment, despite
359 negative CRP values [7]. The authors of a previous study proposed that residual MMP-3
360 activity is one of the responsible factors [17]. Our study showed a greater progression of
361 joint destruction in the MMP-3(+) group than in the MMP-3(-) group, despite arthritis being
362 well controlled by MTX therapy. This was evidenced by the negative CRP values and the
363 absence of swollen joints at 52 weeks. Furthermore, we found no correlation between CRP
364 and MMP-3 levels. These results suggest that persistently high serum MMP-3 levels lead to
365 joint destruction in patients with RA, including those in remission or with LDA.

366 During RA treatment, PSL administration is considered to provide a good
367 therapeutic effect when used in appropriate doses [6]; however, serum MMP-3 levels tend
368 to increase via an unknown mechanism [18, 19]. If this PSL-induced elevation of serum
369 MMP-3 is simply affected by the detection of serum MMP-3 in the clinical laboratory and is
370 not related to the pathophysiology of RA, joint destruction should progress more in the
371 PSL(-) group than in the PSL(+) group when their MMP-3 values are the same. However, our
372 results showed that the PSL-treated group had the same mean Δ mTSS and progression rates
373 of joint destruction as the PSL-free group. To exclude the possibility that PSL was
374 administered to patients with high disease activity, we investigated whether there was a
375 correlation between disease activity and PSL usage. We found no significant differences in

376 disease activity between the PSL (-) and PSL (+) groups. Furthermore, we observed no
377 correlation between the PSL dose and the serum MMP-3 level. These data suggest that the
378 PSL-induced increase in serum MMP-3 levels is also involved in the progression of joint
379 destruction. To the best of our knowledge, this is the first report to show that a PSL-induced
380 increase in serum MMP-3 levels is involved in joint destruction.

381 Interestingly, while we selected patients in remission or with LDA at baseline, the
382 MMP-3(+) group had significantly higher mean Δ mTSS and progression rates of joint
383 destruction than the MMP-3(-) group. Although it has been reported that joint destruction
384 is correlated with disease activity [20], our results suggest that serum MMP-3 values are
385 more important compared to DAS28-ESR and CDAI as an indicator of the radiographic
386 progression of joint destruction. There was no correlation between DAS28 and MMP-3 or
387 between CDAI and MMP-3 in patients with LDA or remission (data not shown). These results
388 also suggest that serum MMP-3 levels serve as an indicator of joint destruction, which
389 implies that even with reduced inflammation and improved disease activity to LDA or
390 remission, joint destruction progression may still occur unless serum MMP-3 levels are
391 appropriately managed.

392 Previous studies have reported cutoff values for serum MMP-3 levels to prevent
393 joint destruction [21,22]. These studies included RA patients with positive CRP values, high
394 disease activity, and receiving PSL treatment. Furthermore, these studies calculated the
395 cutoff value from a patient cohort comprising both sexes, despite different upper limit
396 values of the reference range. In the present study, we analyzed the cutoff values for PSL-
397 free female patients with RA, negative CRP values, and remission or LDA. In the ROC analysis,

398 the appropriate cutoff value of serum MMP-3 levels was found to be 49.7 ng/mL for
399 preventing the progression of joint destruction in female patients; this value falls below the
400 upper limit of the reference range (59.7 ng/mL). Serum MMP-3 levels may be a better
401 indicator of whether joint destruction is likely to progress and suggest treatment
402 intensification, even if disease activity and CRP levels have remained low for up to 1 year.
403 The current reference range of serum MMP-3 was determined based on reference
404 individuals who met the following conditions: negative CRP values, negative RF values,
405 normal fasting blood sugar levels, and normal liver enzyme test results. However, these
406 conditions do not exclude potential RA patients. Thus, it is not surprising that our cutoff
407 value was lower than the upper limit of the reference range of serum MMP-3 [23].

408 MMP-3 can activate several other MMPs, including MMP-1, MMP-7, and MMP-9,
409 thereby increasing connective tissue matrix proteolysis [24]. It is thought that these
410 proteases contribute to joint destruction, either directly or indirectly, by degrading the
411 cartilage extracellular matrix [9, 11]. Thus, it is difficult to achieve structural remission unless
412 serum MMP-3 levels are reduced to an appropriate level. However, there are currently no
413 therapeutic agents that directly lower serum MMP-3 levels. In our *in vitro* experiment, TNF-
414 alpha-induced increase in MMP-3 levels from RA synoviocytes was inhibited by PSL (data not
415 shown); however, oral PSL administration increases serum MMP-3 levels *in vivo* [19]. In
416 order to develop new treatments that can decrease the serum MMP-3 levels to prevent joint
417 destruction in RA, it is necessary to elucidate the mechanism of the PSL-induced increase in
418 serum MMP-3 levels or develop new therapeutic agents that lower MMP-3 levels.

419

420 **Limitations**

421 This study has some limitations. The retrospective design limits the ability to draw
422 causal inferences. The sample size is relatively small, and the findings may not be
423 generalizable. The sample is predominantly from two university hospitals in the Kansai Area,
424 Japan, which may limit generalizability. The number of male patients was too small to
425 determine the adequate cutoff value of serum MMP-3 levels to prevent the progression of
426 joint destruction in males. Joint destruction lasting longer than 52 weeks was not estimated.

427

428 **Conclusion**

429 Our study indicates that residual MMP-3 activity, regardless of PSL administration, may lead
430 to the progression of joint destruction in RA patients even after achieving clinical remission
431 or LDA through successful treatment with MTX. Intensification of therapy may be necessary
432 to achieve structural remission in female RA patients with serum MMP-3 levels of 49.7
433 ng/ml or higher.

434 REFERENCES

- 435 1. Koch AE (2007) The pathogenesis of rheumatoid arthritis. *Am J Orthop (Belle Mead*
436 *NJ)* 36:5–8
- 437 2. Smolen JS, Aletaha D, Bijlsma JWJ et al (2010) Treating rheumatoid arthritis to target:
438 Recommendations of an international task force. *Ann Rheum Dis* 69:631–637.
439 <https://doi.org/10.1136/ard.2009.123919>
- 440 3. Smolen JS, Breedveld FC, Burmester GR et al (2016) Treating rheumatoid arthritis to
441 target: 2014 update of the recommendations of an international task force. *Ann*
442 *Rheum Dis* 75:3–15. <https://doi.org/10.1136/annrheumdis-2015-207524>
- 443 4. Cronstein BN (2005) Low-dose methotrexate: A mainstay in the treatment of
444 rheumatoid arthritis. *Pharmacol Rev* 57:15914465. <https://doi.org/10.1124/pr.57.2.3>
- 445 5. Pincus T, Yazici Y, Sokka T et al (2003) Methotrexate as the “anchor drug” for the
446 treatment of early rheumatoid arthritis. *Clin Exp Rheumatol* 21:S179–S185
- 447 6. Smolen JS, Landewé RBM, Bijlsma JWJ et al (2020) EULAR recommendations for the
448 management of rheumatoid arthritis with synthetic and biological disease-modifying
449 antirheumatic drugs: 2019 update. *Ann Rheum Dis* 79:S685–S699.
450 <https://doi.org/10.1136/annrheumdis-2019-216655>
- 451 7. Smolen JS, Van Der Heijde DMFM, St.Clair EW et al (2006) Predictors of joint damage
452 in patients with early rheumatoid arthritis treated with high-dose methotrexate with
453 or without concomitant infliximab: Results from the ASPIRE trial. *Arthritis Rheum*

- 454 54:702–710. <https://doi.org/10.1002/art.21678>
- 455 8. Malesud CJ (2006) Matrix metalloproteinases (MMPs) in health and disease: An
456 overview. *Front Biosci* 11:1696–1701. <https://doi.org/10.2741/1915>
- 457 9. Yasuo Y, Hiroyuki N, Ken'ichi O et al (2000) Matrix metalloproteinases and tissue
458 inhibitors of metalloproteinases in synovial fluids from patients with rheumatoid
459 arthritis or osteoarthritis. *Ann Rheum Dis* 59:455–461.
460 <https://doi.org/10.1136/ard.59.6.455>
- 461 10. Cawston T (1998) Matrix metalloproteinases and TIMPs: Properties and implications
462 for the rheumatic diseases. *Mol Med Today* 4:130–137.
463 [https://doi.org/10.1016/S1357-4310\(97\)01192-1](https://doi.org/10.1016/S1357-4310(97)01192-1)
- 464 11. Okada Y (2000) Matrix-degrading metalloproteinases and their roles in joint
465 destruction. *Mod Rheumatol* 10:121–128. <https://doi.org/10.3109/s101650070018>
- 466 12. Lerner A, Neidhöfer S, Reuter S, Matthias T (2018) MMP3 is a reliable marker for
467 disease activity, radiological monitoring, disease outcome predictability, and
468 therapeutic response in rheumatoid arthritis. *Best Pract Res Clin Rheumatol* 32:550–
469 562. <https://doi.org/10.1016/j.berh.2019.01.006>
- 470 13. Kobayashi A, Naito S, Enomoto H et al (2007) Serum levels of matrix
471 metalloproteinase 3 (stromelysin 1) for monitoring synovitis in rheumatoid arthritis.
472 *Arch Pathol Lab Med* 131:563–570. [https://doi.org/10.1043/1543-2165\(2007\)131](https://doi.org/10.1043/1543-2165(2007)131)
- 473 14. Hattori Y, Kida D, Kaneko A (2019) Normal serum matrix metalloproteinase-3 levels

- 474 can be used to predict clinical remission and normal physical function in patients with
475 rheumatoid arthritis. *Clin Rheumatol* 38:181–187. [https://doi.org/10.1007/s10067-](https://doi.org/10.1007/s10067-017-3829-9)
476 017-3829-9
- 477 15. Yoshimi R, Hama M, Takase K et al (2013) Ultrasonography is a potent tool for the
478 prediction of progressive joint destruction during clinical remission of rheumatoid
479 arthritis. *Mod Rheumatol* 23:456–465. <https://doi.org/10.1007/s10165-012-0690-1>
- 480 16. Bruynesteyn K, Boers M, Kostense P et al (2005) Deciding on progression of joint
481 damage in paired films of individual patients: Smallest detectable difference or
482 change. *Ann Rheum Dis* 64:179–182. <https://doi.org/10.1136/ard.2003.018457>
- 483 17. Konishi H, Kanou SE, Yukimatsu R et al (2022) Adenosine inhibits TNF α -induced MMP-
484 3 production in MH7A rheumatoid arthritis synoviocytes via A2A receptor signaling.
485 *Sci Rep* 12:1–9. <https://doi.org/10.1038/s41598-022-10012-6>
- 486 18. Hattori Y, Kida D, Kaneko A (2018) Steroid therapy and renal dysfunction are
487 independently associated with serum levels of matrix metalloproteinase-3 in patients
488 with rheumatoid arthritis. *Mod Rheumatol* 28:242–248.
489 <https://doi.org/10.1080/14397595.2017.1354431>
- 490 19. Ribbens C, Martin y Porras M, Franchimont N, Kaiser M, Jaspar J, Damas P, Houssiau
491 FMM (2002) Increased matrix metalloproteinase-3 serum levels in rheumatic
492 diseases: Relationship with synovitis and steroid treatment. *Ann Rheum Dis* 61:161–
493 166. <https://doi.org/10.1136/ard.61.2.161>
- 494 20. Tsuji H, Yano K, Furu M et al (2017) Time-averaged disease activity fits better joint

- 495 destruction in rheumatoid arthritis. *Sci Rep* 7:1–8. [https://doi.org/10.1038/s41598-](https://doi.org/10.1038/s41598-017-05581-w)
496 017-05581-w
- 497 21. Mamehara A, Sugimoto T, Sugiyama D et al (2010) Serum matrix metalloproteinase-3
498 as predictor of joint destruction in rheumatoid arthritis, treated with non-biological
499 disease modifying anti-rheumatic drugs. *Kobe J Med Sci* 56:98–107
- 500 22. Maksymowych WP, Landewé R, Conner-Spady B et al (2007) Serum matrix
501 metalloproteinase 3 is an independent predictor of structural damage progression in
502 patients with ankylosing spondylitis. *Arthritis Rheum* 56:1846–1853.
503 <https://doi.org/10.1002/art.22589>
- 504 23. Yumeto N, Yuko T, Satoshi N et al (2014) Basic study of reagents for measurement of
505 matrix metalloproteinase-3. *Igakukensa* 63:579–585.
506 <https://doi.org/10.1007/s12291-010-0025-y>
- 507 24. Ogata Y, Enghild JJ, Nagase H (1992) Matrix metalloproteinase 3 (stromelysin)
508 activates the precursor for the human matrix metalloproteinase 9. *J Biol Chem*
509 267:3581–3584. [https://doi.org/10.1016/S0021-9258\(19\)50563-4](https://doi.org/10.1016/S0021-9258(19)50563-4)
- 510
- 511